ENDLOS-TURBO PUT - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 01:04:46 29/06/2024 am IST | ||
| 2.01 EUR | +14.86% |
|
| Current month | -40.00% | ||
| 1 month | -48.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.01 | +14.86% |
| 27/24/27 | 1.75 | -4.37% |
| 26/24/26 | 1.83 | -3.17% |
| 25/24/25 | 1.89 | +15.95% |
| 24/24/24 | 1.63 | -23.83% |
Delayed Quote Deutsche Boerse AG
Last update June 29, 2024 at 01:04 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ2B6W |
| ISIN | DE000DJ2B6W7 |
| Date issued | 11/09/2023 |
| Strike | 488 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.57 € |
|---|---|
| Lowest since issue | 0.63 € |
| Spread | 0.26 € |
| Spread % | 10.79% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
